Longde Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Longde Wang has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Xiaojuan Du
Clinical College of Traditional Chinese Medicine, Gansu University of Traditional Chinese Medicine, Lanzhou, China
2 shared publicationsYuanyuan Niu
Clinical College of Traditional Chinese Medicine, Gansu University of Traditional Chinese Medicine, Lanzhou, China
2 shared publicationsZhengju Li
Clinical College of Traditional Chinese Medicine, Gansu University of Traditional Chinese Medicine, Lanzhou, China
2 shared publications- Banghan Ding
The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
1 shared publication - Bing Feng
The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, 510120, China
1 shared publication - Bo Yu
General Surgery, The Second People’s Hospital of Lanzhou, Lanzhou, China
1 shared publication
Latest Publications
- Open Access
- 25 November 2024
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 11, 1491009
Progress in the mechanism of functional dyspepsia: roles of mitochondrial autophagy in duodenal abnormalities
Mitochondria are the main source of energy for cellular activity. Their functional damage or deficiency leads to cellular deterioration, which in turn triggers autophagic reactions. Taking mitochondrial autophagy as a starting point, the present review explored the mechanisms of duodenal abnormalities in detail, including mucosal barrier damage, release of inflammatory factors, and disruption of intracellular signal transduction. We summarized the key roles of mitochondrial autophagy in the abnormal development of the duodenum and examined the in-depth physiological and pathological mechanisms involved, providing a comprehensive theoretical basis for understanding the pathogenesis of functional dyspepsia. At present, it has been confirmed that an increase in the eosinophil count and mast cell degranulation in the duodenum can trigger visceral hypersensitive reactions and cause gastrointestinal motility disorders. In the future, it is necessary to continue exploring the molecular mechanisms and signaling pathways of mitochondrial autophagy in duodenal abnormalities. A deeper understanding of mitochondrial autophagy provides important references for developing treatment strategies for functional dyspepsia, thereby improving clinical efficacy and patient quality of life.
- 25 November 2024
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 11, 1491009
Open AccessProgress in the mechanism of functional dyspepsia: roles of mitochondrial autophagy in duodenal abnormalities
Mitochondria are the main source of energy for cellular activity. Their functional damage or deficiency leads to cellular deterioration, which in turn triggers autophagic reactions. Taking mitochondrial autophagy as a starting point, the present review explored the mechanisms of duodenal abnormalities in detail, including mucosal barrier damage, release of inflammatory factors, and disruption of intracellular signal transduction. We summarized the key roles of mitochondrial autophagy in the abnormal development of the duodenum and examined the in-depth physiological and pathological mechanisms involved, providing a comprehensive theoretical basis for understanding the pathogenesis of functional dyspepsia. At present, it has been confirmed that an increase in the eosinophil count and mast cell degranulation in the duodenum can trigger visceral hypersensitive reactions and cause gastrointestinal motility disorders. In the future, it is necessary to continue exploring the molecular mechanisms and signaling pathways of mitochondrial autophagy in duodenal abnormalities. A deeper understanding of mitochondrial autophagy provides important references for developing treatment strategies for functional dyspepsia, thereby improving clinical efficacy and patient quality of life.
- 8 December 2022
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 35 (2) , 133-152
A review of edible plant-derived natural compounds for the therapy of liver fibrosis
Liver fibrosis has a high incidence worldwide and is the common pathological basis of many chronic liver diseases. Liver fibrosis is caused by the excessive deposition of extracellular matrix and concomitant collagen accumulation in livers and can lead to the development of liver cirrhosis and even liver cancer. A large number of studies have provided evidence that liver fibrosis can be blocked or even reversed by appropriate medical interventions. However, the antifibrosis drugs with ideal clinical efficacy are still insufficient. The edible plant-derived natural compounds have been reported to exert effective antifibrotic effects with few side-effects, representing a kind of promising source for the treatment of liver fibrosis. In this article, we reviewed the current progress of the natural compounds derived from dietary plants in the treatment of liver fibrosis, including phenolic compounds (capsaicin, chlorogenic acid, curcumin, ellagic acid, epigallocatechin-3-gallate, resveratrol, sinapic acid, syringic acid, vanillic acid and vitamin E), flavonoid compounds (genistein, hesperidin, hesperetin, naringenin, naringin and quercetin), sulfur-containing compounds (S-allylcysteine, ergothioneine, lipoic acid and sulforaphane) and other compounds (betaine, caffeine, cucurbitacin B, lycopene, α-mangostin, γ-mangostin, ursolic acid, vitamin C and yangonin). The pharmacological effects and related mechanisms of these compounds in in-vivo and in-vitro models of liver fibrosis are focused.
- 8 December 2022
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 35 (2) , 133-152
A review of edible plant-derived natural compounds for the therapy of liver fibrosis
Liver fibrosis has a high incidence worldwide and is the common pathological basis of many chronic liver diseases. Liver fibrosis is caused by the excessive deposition of extracellular matrix and concomitant collagen accumulation in livers and can lead to the development of liver cirrhosis and even liver cancer. A large number of studies have provided evidence that liver fibrosis can be blocked or even reversed by appropriate medical interventions. However, the antifibrosis drugs with ideal clinical efficacy are still insufficient. The edible plant-derived natural compounds have been reported to exert effective antifibrotic effects with few side-effects, representing a kind of promising source for the treatment of liver fibrosis. In this article, we reviewed the current progress of the natural compounds derived from dietary plants in the treatment of liver fibrosis, including phenolic compounds (capsaicin, chlorogenic acid, curcumin, ellagic acid, epigallocatechin-3-gallate, resveratrol, sinapic acid, syringic acid, vanillic acid and vitamin E), flavonoid compounds (genistein, hesperidin, hesperetin, naringenin, naringin and quercetin), sulfur-containing compounds (S-allylcysteine, ergothioneine, lipoic acid and sulforaphane) and other compounds (betaine, caffeine, cucurbitacin B, lycopene, α-mangostin, γ-mangostin, ursolic acid, vitamin C and yangonin). The pharmacological effects and related mechanisms of these compounds in in-vivo and in-vitro models of liver fibrosis are focused.
- Open Access
Effectiveness of Inactivated COVID-19 Vaccines against COVID-19 Caused by the SARS-CoV-2 Delta and Omicron Variants: A Retrospective Cohort Study
Background: Real-world evidence on the effectiveness of inactivated vaccines against the Delta and Omicron (BA.2.38) variants remains scarce. Methods: A retrospective cohort study was conducted to estimate the adjusted vaccine effectiveness (aVE) of one, two, and three doses of inactivated vaccines in attenuating pneumonia, severe COVID-19, and the duration of viral shedding in Delta and Omicron cases using modified Poisson and linear regression as appropriate. Results: A total of 561 COVID-19 cases were included (59.2% Delta and 40.8% Omicron). In total, 56.4% (184) of Delta and 12.0% (27) of Omicron cases had COVID-19 pneumonia. In the two-dose vaccinated population, 1.4% of Delta and 89.1% of Omicron cases were vaccinated for more than 6 months. In Delta cases, the two-dose aVE was 52% (95% confidence interval, 39–63%) against pneumonia and 61% (15%, 82%) against severe disease. Two-dose vaccination reduced the duration of viral shedding in Delta cases, but not in booster-vaccinated Omicron cases. In Omicron cases, three-dose aVE was 68% (18%, 88%) effective against pneumonia, while two-dose vaccination was insufficient for Omicron. E-values were calculated, and the E-values confirmed the robustness of our findings. Conclusions: In Delta cases, two-dose vaccination within 6 months reduced pneumonia, disease severity, and the duration of viral shedding. Booster vaccination provided a high level of protection against pneumonia with Omicron and should be prioritized.
Open AccessEffectiveness of Inactivated COVID-19 Vaccines against COVID-19 Caused by the SARS-CoV-2 Delta and Omicron Variants: A Retrospective Cohort Study
Background: Real-world evidence on the effectiveness of inactivated vaccines against the Delta and Omicron (BA.2.38) variants remains scarce. Methods: A retrospective cohort study was conducted to estimate the adjusted vaccine effectiveness (aVE) of one, two, and three doses of inactivated vaccines in attenuating pneumonia, severe COVID-19, and the duration of viral shedding in Delta and Omicron cases using modified Poisson and linear regression as appropriate. Results: A total of 561 COVID-19 cases were included (59.2% Delta and 40.8% Omicron). In total, 56.4% (184) of Delta and 12.0% (27) of Omicron cases had COVID-19 pneumonia. In the two-dose vaccinated population, 1.4% of Delta and 89.1% of Omicron cases were vaccinated for more than 6 months. In Delta cases, the two-dose aVE was 52% (95% confidence interval, 39–63%) against pneumonia and 61% (15%, 82%) against severe disease. Two-dose vaccination reduced the duration of viral shedding in Delta cases, but not in booster-vaccinated Omicron cases. In Omicron cases, three-dose aVE was 68% (18%, 88%) effective against pneumonia, while two-dose vaccination was insufficient for Omicron. E-values were calculated, and the E-values confirmed the robustness of our findings. Conclusions: In Delta cases, two-dose vaccination within 6 months reduced pneumonia, disease severity, and the duration of viral shedding. Booster vaccination provided a high level of protection against pneumonia with Omicron and should be prioritized.
- Open Access
- 1 January 2018
- Published by ACT Publishing Group in Journal of Gastroenterology and Hepatology Research
- Vol. 7 (1) , 2521-2529
The Changes of Brain-gut SP and VIP Levels in the Rats with Functional Dyspepsia and the Intervention of Pingwei Capsule
AIM: To explore the levels of substance P (SP) and vasoactive intestinal peptide (VIP) in the brain–gut axis of rats with functional dyspepsia (FD) and the intervention of Pingwei capsule. METHODS: FD model rats were established by stimulating semi-starved rats via tail damping, provocation, and forced exercise fatigue. Then, the rats were treated with domperidone and Traditional Chinese Medicine, Pingwei capsule, for 3 weeks.The rates of the rat intestinal propulsion and gastric emptying were observed and the levels of SP and VIP were detected in serum by the enzyme-linked immunosorbent assay(ELISA), and in antrum, duodenum and hypothalamus by reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry. RESULTS: FD rats were less active, nervous, anxious and dysphoria, loose stool was observed, the bodyweight and food intake decreased obviously, and their intestinal propulsion and gastric emptying slowed down markedly. Molecular biological experiments showed that the mRNA and protein expressions of SP and VIP increased significantly in antrum, duodenum, and hypothalamus of FD rats, but the SP level markedly decreased in serum compared with that in the control group. Domperidone and Pingwei capsule could improve the behavioral performances and intestinal propulsion and gastric emptying , and decrease the expressions of SP and VIP in brain–gut axis of FD rats. CONCLUSION: There appear abnormal behaviors, dysmotility gastrointestinal disorders and parasecretion of brain-gut SP and VIP in FD rats. Similarity to domperidone, Pingwei capsule has a degree of therapeutic effects in rats with FD.
- 1 January 2018
- Published by ACT Publishing Group in Journal of Gastroenterology and Hepatology Research
- Vol. 7 (1) , 2521-2529
Open AccessThe Changes of Brain-gut SP and VIP Levels in the Rats with Functional Dyspepsia and the Intervention of Pingwei Capsule
AIM: To explore the levels of substance P (SP) and vasoactive intestinal peptide (VIP) in the brain–gut axis of rats with functional dyspepsia (FD) and the intervention of Pingwei capsule. METHODS: FD model rats were established by stimulating semi-starved rats via tail damping, provocation, and forced exercise fatigue. Then, the rats were treated with domperidone and Traditional Chinese Medicine, Pingwei capsule, for 3 weeks.The rates of the rat intestinal propulsion and gastric emptying were observed and the levels of SP and VIP were detected in serum by the enzyme-linked immunosorbent assay(ELISA), and in antrum, duodenum and hypothalamus by reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry. RESULTS: FD rats were less active, nervous, anxious and dysphoria, loose stool was observed, the bodyweight and food intake decreased obviously, and their intestinal propulsion and gastric emptying slowed down markedly. Molecular biological experiments showed that the mRNA and protein expressions of SP and VIP increased significantly in antrum, duodenum, and hypothalamus of FD rats, but the SP level markedly decreased in serum compared with that in the control group. Domperidone and Pingwei capsule could improve the behavioral performances and intestinal propulsion and gastric emptying , and decrease the expressions of SP and VIP in brain–gut axis of FD rats. CONCLUSION: There appear abnormal behaviors, dysmotility gastrointestinal disorders and parasecretion of brain-gut SP and VIP in FD rats. Similarity to domperidone, Pingwei capsule has a degree of therapeutic effects in rats with FD.